Theocharis Koufakis, Alexander Kokkinos, Carel W. le Roux
Obesity is a chronic, biologically defended disease, yet its clinical management continues to be shaped by behavioural paradigms that no longer reflect contemporary science, especially outside specialist services. While lifestyle factors such as dietary patterns, physical inactivity, sleep disruption and other environmental influences contribute to obesity development, they do not fully explain or reverse the neuroendocrine mechanisms that defend elevated adiposity. Although calorie restriction can produce short-term metabolic improvements, including improved insulin resistance, it does not modify the underlying neuroendocrine drivers of adipocyte mass regulation; consequently, exclusive reliance on calorie-restriction-centred models may delay the introduction of mechanism-based treatments and allow obesity-related complications to recur or progress over time. In contrast, modern pharmacotherapies act directly on the regulatory systems governing adipocyte mass and thus affect appetite, energy homeostasis and metabolic adaptation, producing durable improvements across cardiometabolic, hepatic, respiratory and musculoskeletal domains. Safety profiles for obesity medications are well characterised, and for appropriately selected patients the benefit-risk balance is favourable. Prevention efforts remain essential, but no population-level strategy has yet demonstrated sustained impact on obesity prevalence. Conceptual analogies help clarify these distinctions: carrying additional weight, like a heavy backpack, does not in itself constitute a disease and treating established pathology cannot depend on upstream environmental reform, just as anaphylaxis cannot be managed by regulating peanut exposure alone. A therapeutic framework grounded in biological mechanisms rather than behavioural assumptions is now both possible and necessary to close long-standing gaps in obesity care.